tirzepatide gip analog Effects of tirzepatide, a dual and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats Tirzepatide Explained: The Future of

Breastfeeding considerations Limited research exists on the safety of GLP-1 agonists during breastfeeding

The primary outcome was time to first stroke event during follow-up

Initial Wegovy Injection Dose Escalation Schedule (all indications) Week 1 to week 4: 0.25mg once a week Week 5 to week 8: 0.5mg once a week Week 9 to week 12: 1mg once a week Week 13 to week 16: 1.7mg once a week Maintenance injection dose guidance Adult weight reduction maintenance dose: 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly

This work was supported by the National Institutes of Health under award numbers 2R01HL115189, P30DK04056, UE5DK137285, and U24 DK132733, and by the National Clinician Scholars Program at the Duke Clinical and Translational Science Institute